Lek Expands Biopharmaceutical Capabilities

Staking a prominent claim in the pharmaceutical sector experiencing the strongest growth, Slovenian firm Lek - part of Swiss firm Novartis' Sandoz generics division - has started construction of a new biopharmaceutical development centre just outside the country's capital, Ljubljana. BMI sees the announcement as strongly positive for Lek, which posted robust financial results last

To read the full article, please choose one of the following options: